As we move from 2018 into 2019, the pharma industry has certainly seen some new changes and developments and this shows no signs of changing with many more technological advancements set to continue into 2019. Read all about these trends and innovations in the Nov/Dec issue of Pharmaceutical Processing.
A significant amount of time and money is invested in your process equipment to protect your employees and maximise the quality of high value ingredients and formulations. You also invest a lot of resources into the regular maintenance of critical equipment, such as replacement of filters and seals in isolators, air locks and cleanroom HVAC- But do you invest enough time and pay the same attention to maintaining your split butterfly valves?
As more pharmaceutical businesses focus on creating innovative, targeted therapies, the industry is having to adapt like never before. Contamination control in particular has advanced and developed significantly.
Global product manager, Michael Avraam, discusses how businesses are transforming their approaches to containment and the safe development of pharmaceutical products in an article for Pharmaceutical Manufacturing.
Ensuring a safe and sterile environment for active pharmaceutical ingredients (APIs) and formulation ingredients is fundamental during aseptic processing. Air filtration systems, materials transfer and of course operators themselves bring an abundance of potential hazards during the manufacturing process. Therefore there have been many techniques developed in order to provide a risk-averse and contamination-free environment for production.
ChargePoint Technology's global product manager, Christian Dunne discusses the various techniques available with Pharmaceutical Manufacturing. From barrier technologies such as isolators and RABS to split butterfly valve technology (SBV), Christian weighs up the benefits of each and their place within the sector. You can read the full article here
As the demand for high potency drug handling continues to rise, as does the need for high containment facilities. However, currently many manufacturing facilities are unable to manage the upsurge and are needing to upgrade, develop and sometimes even construct new facilities to handle the significant demand. Under these circumstances it is more important than ever for companies to select the right partners with specialist containment solutions so they can adapt to the industry changes and containment challenges ahead.
Our very own Michael Avraam discusses the risks, challenges and innovative steps now being taken in today's high potency sector with CPhI Online. You can read the full Q&A here.